MBBEONE@EC2605A

Guopharma Completes First Delivery of BeiGene's New Product

Hong Kong Connect Innovative Drug ETF Pullback, Component Stocks Show Divergent Performance

BeiGene's Novel BCL2 Inhibitor Beyla® Obtains Conditional Approval from NMPA

National Medical Insurance Bureau Launches Innovative Drug Directory for Commercial Health Insurance

Macquarie Analyst Maintains Buy Rating on BeiGene

BeiGene Establishes A-Share Raising Fund Management System

UOB Securities Analysts Positive on BeiGene's Revenue Growth Potential

Two Drugs of BeiGene Entered the Commercial Insurance Innovative Drugs Directory

Brokers Adjust Ratings and Target Prices for Multiple Stocks

BeiGene's Q3 Total Revenue Reached 1.4 Billion USD, Up 41% YoY

BeiGene Adds Gene Editing Concept, Expanding Cell Therapy

Beyter Zhishen Reports Better-than-Expected Q3 2025 Earnings, Upgrading Full-Year Guidance

Beigene Reports Significant Q3 2025 Revenue Growth

TF Securities Upgrades BeiGene's Earnings Forecast and Maintains Buy Rating

CMBI Raises Profit Forecast and Maintains Buy Rating for BeiGene

MUFG and Huachuang Maintain Buy Rating on BeiGene

BGBA's Brukinsa Surpasses Expectations, Leading in BTK Inhibitors Market

CLSA Analyst Reiterates Buy Rating on BeiGene

Morgan Stanley Reaffirms Buy Rating on BeiGene

Huatai Securities Raises Rating and Target Price for BeiGene

BOER POWER

WAI CHUN GROUP

HUAYUEXPRESSWAY

ASIA ENERGY LOG

KNOWLEDGE ATLAS

HING LEE (HK)

JH EDUCATION

TBKS HLDGS

SIMPLICITY HLDG

06160

159316

159892

159102

520880

513700

520690

159506

513120

On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound, the overall trend showed weakness. Currently, the pharmaceutical sector is relatively mild, with some long-term funds testing the waters as the market rebounds. The main operators displayed clear hesitation and repetition, with the day's rhythm primarily characterized by strong fluctuations. Recently, the market has focused on news such as "new contracts flowing out of the CXO business," which has activated short-term funds related to pharmaceuticals. However, despite increased trading volume, the main funds still primarily engaged in range trading, leading to intensified overall bullish-bearish divergence and a strong wait-and-see atmosphere. The MACD daily signal has shown some phase repair, but the resistance area above the stock price and long-term pressure remain heavy, with no clear signs of sustained upward movement from the main operators. On the news front, there are currently no major disturbances in the pharmaceutical sector, and thematic rotations and active funds have revealed structural opportunities. The intraday performance showed a high opening and pullback, with multiple tests of the 20-day line, where right-side funds dominated the intraday game. However, the volume cooperation was limited, restricting the rebound space, and the signals from large orders were scattered. Overall, a new round of regulatory details for the pharmaceutical industry is about to be released, becoming a key focus for the market and significantly impacting the sector's trend. The risk exposure cannot be ignored; if negative news arises or the main operators significantly reduce their holdings, the pressure will intensify. It is recommended to continue monitoring policy dynamics and changes in the pharmaceutical sector's hotspots, dynamically managing positions to cope with uncertainties

Technical Forecast

BEONE MEDICINES

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

BEONE MEDICINES (6160.HK): Range-bound fluctuations, cautious and repeated capital movements, the pharmaceutical sector's new regulations lead to increasingly complex speculation

BGNE

688235

YUMC

09987

CICC released a report predicting potential companies for inclusion in the Hang Seng Index's semi-annual adjustment, including Zijin Mining International, Beigene, YUM China, etc., along with the possible weight and capital inflow situation. At the same time, companies such as Standard Chartered and Swire Properties may be included in the Hang Seng Index as replacements due to the delisting of Hang Seng Bank

AASTOCKS

Beigene

BeOne Medicines

YUM China

YUM CHINA

In "Major Banks," CICC lists potential "blue-chip" companies for the Hang Seng Index's semi-annual adjustment (table)

China National Pharmaceutical Group announced that as the preferred distributor for BeiGene's new product "BaYueDa" in Beijing, it successfully completed the first order delivery for BeiGene yesterday (14th). The medication arrived at China National Pharmaceutical Group's logistics in the afternoon of the same day, and with the cooperation and coordination of relevant departments such as the procurement center, Beijing direct sales center, and China National Pharmaceutical Group logistics, it was delivered to the designated DTP pharmacy within 3 hours after arrival

Beigene's "BeYueDa" completes its first sale in Beijing

603259

02359

HKXCY

00388

Hong Kong Exchanges and Clearing (HKEX) announced that it will launch six new categories of stock options on January 19, 2026, to expand the stock options market and provide more choices for investors. Last year, the average daily trading volume of the derivatives market at HKEX reached a new high, and the average daily trading volume of stock options also increased significantly. The newly launched options include stocks from companies such as Zijin Mining, Wuxi AppTec, and Beigene, with contract trading units and expiration months already announced

港交所

WuXi AppTec

WUXI APPTEC

Hong Kong Exchanges and Clearing (HKEX)

HKEX

Hong Kong Exchanges and Clearing (HKEX) launches new stock options category

$Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticalsmp.weixin.qq.com/s/gihUP-...

当前环境异常，完成验证后即可继续访问。

Zai Lab

ZAI LAB

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

WUXI BIO

WuXi Biologics

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks opened high and moved higher, with technology stocks and pharmaceutical stocks rising together. The technology index rose 2.35%, Tencent Music surged more than 15% after earnings, and Alibaba rose more than 4%.

BABA-WR

BABA-W

Alibaba HK SDR 5to1

Alibaba

Tencent Music

TME-SW

VIVA BIOTECH

JOINN

Asymchem

CHINA LIT

CANBRIDGE-B

MEITUAN

MEITUAN-WR

Meituan HK SDR 5to1

Meituan

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

KUAISHOU-W

KUAISHOU-WR

FIT HON TENG

BYD ELECTRONIC

AB&B BIO-TECH-B

BILIBILI-W

Bilibili

BIDU-SW

BIDU-SWR

Baidu

Q TECH

PHARMARON

Pharmaron

JD-SW

JD-SWR

JD HK SDR 10to1

JD.com

AAC TECH

WEIMOB INC

Hong Kong stock hot trading (8.13)｜ Hong Kong technology stocks fully exploded, Tencent hit a four-year high, Alibaba surged over 4%

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

POP MART

MIXUE GROUP

GUMING

AIA Group

LIANLIAN

OSL GROUP

HENGRUI PHARMA

Hengrui Pharma

PICC P&C

MAO GEPING

BLOKS

CITIC SEC

CITIC Securities Co., Ltd.

EB SECURITIES

EBSCN

CHINA LIFE

China Life

CHICMAX

CHINA EB LTD

LINKLOGIS-W

CICC

Circle

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

The annual portfolio return for 2024 is around 8%, far below expectations. This is mainly due to significant negative contributions from $PDD(PDD.US) and $Li Auto(LI.US).Tonight, I will open a new U.S. stock portfolio for 2025, mainly considering the following:1. Remove Li Auto, continue to hold Pinduoduo and Futu, with a low proportion in Futu, planning to trade when it reaches a new high.2. The pharmaceutical sector has been bearish for 4 years, remove XBI, focus on holding one quality pharmaceutical stock each from China and the U.S., BeiGene and Regeneron. Currently, they are both at low positions. Their intrinsic value has been increasing, and in the fifth year, the stock price should change, right?3. The focus in U.S. stocks remains on AI, with slight adjustments. The semiconductor focus is still on TSMC, which is still in a trough. Additionally, shifting towards platforms and applications, optimistic about Claude. Overall, holding Google, Amazon, and Meta. Remove Tesla. New addition is Salesforce, optimistic about AI's early industrialization in the B2B sector.A total of 10 stocks.

Amazon

Alphabet

Alphabet - C

MBBEONE@EC2605A(22174.HK)

BEONE MEDICINES (6160.HK): Range-bound fluctuations, cautious and repeated capital movements, the pharmaceutical sector's new regulations lead to increasingly complex speculation

In "Major Banks," CICC lists potential "blue-chip" companies for the Hang Seng Index's semi-annual adjustment (table)

Beigene's "BeYueDa" completes its first sale in Beijing

Hong Kong Exchanges and Clearing (HKEX) launches new stock options category